Citation Tools
PDF
Other content recommended for you
- Natalizumab and progressive multifocal leucoencephalopathy
- Lessons for clinical trials from natalizumab in multiple sclerosis
- Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring
- No evidence of JC virus reactivation in natalizumab treated multiple sclerosis patients: an 18 month follow-up study
- Switching patients at high risk of PML from natalizumab to another disease-modifying therapy
- Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances
- Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group
- Extended interval dosing of natalizumab in multiple sclerosis
- Update on disease-modifying therapies for multiple sclerosis
- Changes to anti-JCV antibody levels in a Swedish national MS cohort